Imagen

Noticias de última hora

Featured image for “AIM at Melanoma Opens the Second Branch of Fresh Frozen Primary Tissue Bank at Sutter’s California Pacific Medical Center”
09/09/2019

AIM at Melanoma Opens the Second Branch of Fresh Frozen Primary Tissue Bank at Sutter’s California Pacific Medical Center

September 9, 2019 (San Rafael, California) AIM at Melanoma announces the grand opening of the second branch of the International…
Blog - Melanoma360
, 
Noticias de última hora
, 
Investigación sobre el melanoma
Featured image for "AIM en Melanoma abre la primera sucursal del banco de tejidos primarios congelados en el Centro Médico de la Universidad de Pittsburgh (UPMC), Centro Oncológico Hillman"
04/04/2019

AIM at Melanoma abre la primera sucursal del banco de tejidos primarios congelados en el Centro Médico de la Universidad de Pittsburgh (UPMC), Centro Oncológico Hillman

5 de abril de 2019 (San Rafael, California)... AIM en Melanoma anuncia la gran apertura de la primera sucursal de la...
Blog - Melanoma360
, 
Noticias de última hora
, 
Investigación sobre el melanoma
Imagen destacada de "Melanoma International Collaborative Adaptive Trials: Informe de progreso"
11/13/2018

Ensayos colaborativos adaptativos de Melanoma Internacional: Informe de progreso

El primer ensayo de plataforma adaptativa en melanoma -y uno de los únicos ensayos de plataforma adaptativa que existirá durante...
Blog - Melanoma360
, 
Noticias de última hora
, 
Investigación sobre el melanoma
Featured image for “Melanoma Legislation: Progress Report”
11/13/2018

Melanoma Legislation: Progress Report

The facts are straightforward: Indoor tanning before 18 years of age increases one’s risk of melanoma by 85%,1 and the…
Blog - Melanoma360
, 
Noticias de última hora
Featured image for “Global Advocacy: Progress Report”
11/13/2018

Global Advocacy: Progress Report

Melanoma is a global disease. In the United States, one person dies every 54 minutes from melanoma. Australia and New…
Blog - Melanoma360
, 
Noticias de última hora
Featured image for “The Melanoma Tissue Bank: Progress Report”
11/13/2018

The Melanoma Tissue Bank: Progress Report

As we look back through 2018, perhaps the most exciting news from AIM at Melanoma is the progress on what…
Blog - Melanoma360
, 
Noticias de última hora
, 
Investigación sobre el melanoma
Featured image for “AIM Announces New Partnership With The Society for Immunotherapy of Cancer (SITC)”
07/31/2018

AIM Announces New Partnership With The Society for Immunotherapy of Cancer (SITC)

  AIM at Melanoma is proud to announce our new online educational partnership with the Society for Immunotherapy of Cancer…
Blog - Melanoma360
, 
Noticias de última hora
09/09/2019

AIM at Melanoma Opens the Second Branch of Fresh Frozen Primary Tissue Bank at Sutter’s California Pacific Medical Center

September 9, 2019 (San Rafael, California) AIM at Melanoma announces the grand opening of the second branch of the International…
Featured image for “AIM at Melanoma Opens the Second Branch of Fresh Frozen Primary Tissue Bank at Sutter’s California Pacific Medical Center”
Blog - Melanoma360
 | 
Noticias de última hora
 | 
Investigación sobre el melanoma
04/04/2019

AIM at Melanoma abre la primera sucursal del banco de tejidos primarios congelados en el Centro Médico de la Universidad de Pittsburgh (UPMC), Centro Oncológico Hillman

5 de abril de 2019 (San Rafael, California)... AIM en Melanoma anuncia la gran apertura de la primera sucursal de la...
Featured image for "AIM en Melanoma abre la primera sucursal del banco de tejidos primarios congelados en el Centro Médico de la Universidad de Pittsburgh (UPMC), Centro Oncológico Hillman"
Blog - Melanoma360
 | 
Noticias de última hora
 | 
Investigación sobre el melanoma
11/13/2018

Ensayos colaborativos adaptativos de Melanoma Internacional: Informe de progreso

El primer ensayo de plataforma adaptativa en melanoma -y uno de los únicos ensayos de plataforma adaptativa que existirá durante...
Imagen destacada de "Melanoma International Collaborative Adaptive Trials: Informe de progreso"
Blog - Melanoma360
 | 
Noticias de última hora
 | 
Investigación sobre el melanoma
11/13/2018

Melanoma Legislation: Progress Report

The facts are straightforward: Indoor tanning before 18 years of age increases one’s risk of melanoma by 85%,1 and the…
Featured image for “Melanoma Legislation: Progress Report”
Blog - Melanoma360
 | 
Noticias de última hora
11/13/2018

Global Advocacy: Progress Report

Melanoma is a global disease. In the United States, one person dies every 54 minutes from melanoma. Australia and New…
Featured image for “Global Advocacy: Progress Report”
Blog - Melanoma360
 | 
Noticias de última hora
11/13/2018

The Melanoma Tissue Bank: Progress Report

As we look back through 2018, perhaps the most exciting news from AIM at Melanoma is the progress on what…
Featured image for “The Melanoma Tissue Bank: Progress Report”
Blog - Melanoma360
 | 
Noticias de última hora
 | 
Investigación sobre el melanoma
07/31/2018

AIM Announces New Partnership With The Society for Immunotherapy of Cancer (SITC)

  AIM at Melanoma is proud to announce our new online educational partnership with the Society for Immunotherapy of Cancer…
Featured image for “AIM Announces New Partnership With The Society for Immunotherapy of Cancer (SITC)”
Blog - Melanoma360
 | 
Noticias de última hora

Entradas recientes

Featured image for “Celebrate Survivorship – Give Towards Melanoma Research”
Dec. 05, 2023

Celebrate Survivorship – Give Towards Melanoma Research

Featured image for “Melanoma Cancer and Financial Toxicity”
Nov. 14, 2023

Melanoma Cancer and Financial Toxicity

Featured image for “National Family Caregiver Month”
Oct. 31, 2023

National Family Caregiver Month

Featured image for “Immunocore Presents Three-Year Overall Survival Data from the KIMMTRAK Phase 3 Trial”
Oct. 23, 2023

Immunocore Presents Three-Year Overall Survival Data from the KIMMTRAK Phase 3 Trial

Featured image for “Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma”
Oct. 15, 2023

Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma

Filtrar por etiqueta